Shared on04 Sep 25
Analysts remain moderately optimistic on Givaudan, citing long-term benefits from regulatory-driven reformulation and market share gains tempered by near-term margin pressures and valuation concerns, resulting in an unchanged consensus price target of CHF4127. Analyst Commentary Bullish analysts expect Givaudan to benefit from industry-wide reformulation trends starting in 2026 as regulatory pressures phase out synthetic colors and ingredients, particularly in the U.S. Increases in price targets reflect confidence in Givaudan’s ability to capture incremental market share and drive organic growth amid evolving consumer preferences.
Shared on23 Apr 25Fair value Decreased 0.32%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 1.34%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.057%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 0.79%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Decreased 3.19%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.